EF5 PET of Tumor Hypoxia: A Predictive Imaging Biomarker of Response to Stereotactic Ablative Radiotherapy (SABR) for Early Lung Cancer

Abstract

Stereotactic ablative radiotherapy (SABR) has become a new standard of care for early stage lung cancer in patients who are not candidates for surgery because of excessive surgical risk, and will be an important treatment option for a growing segment of patients with lung cancer. This is particularly true as lung cancer screening efforts are expected to diagnose a greater proportion of lung cancers at earlier stages, yet the aging of the population will lead to a greater proportion of patients that increase surgical risk. Tumor hypoxia is a major known mechanism of radiation resistance and is especially expected to affect very short courses of radiation as in SABR. Imaging using a third generation hypoxia PET agent, 18F-EF5, is a promising approach for noninvasive hypoxia measurement that needs to be validated in the clinical setting.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2016
Accession Number
AD1023979

Entities

People

  • Billy Jr W. Loo

Organizations

  • Stanford University

Tags

DTIC Thesaurus Topics

  • Biological Markers
  • Biomedical Research
  • Cancer Screening
  • Clinical Trials
  • Data Analysis
  • Demographic Cohorts
  • Department Of Defense
  • Health Services
  • Institutional Review Board
  • Intervention
  • Lung Cancer
  • Oxygenation
  • Radiation
  • Radiation Resistance
  • Radiotherapy
  • Survival
  • Therapy

Fields of Study

  • Medicine
  • Physics

Readers

  • Oncology (Cancer Research).
  • Polymer Science and Engineering.
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.